- Home
- HASI vs CNTA Comparison
HASI vs CNTA Comparison
Compare HASI & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HASI | CNTA |
|---|---|---|
| Founded | 1981 | 2020 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 3.5B |
| IPO Year | 2012 | 2021 |
Fundamental Metrics
Financial Performance| Metric | HASI | CNTA |
|---|---|---|
| Price | $36.53 | $26.57 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 9 |
| Target Price | ★ $42.38 | $40.89 |
| AVG Volume (30 Days) | 736.7K | ★ 1.1M |
| Earning Date | 05-06-2026 | 05-13-2026 |
| Dividend Yield | ★ 4.77% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.41 | N/A |
| Revenue | ★ $400,502,000.00 | N/A |
| Revenue This Year | $61.10 | N/A |
| Revenue Next Year | $250.69 | N/A |
| P/E Ratio | $25.24 | ★ N/A |
| Revenue Growth | ★ 4.41 | N/A |
| 52 Week Low | $21.98 | $9.60 |
| 52 Week High | $40.01 | $30.58 |
Technical Indicators
Market Signals| Indicator | HASI | CNTA |
|---|---|---|
| Relative Strength Index (RSI) | 52.33 | 49.00 |
| Support Level | $35.26 | $24.62 |
| Resistance Level | $37.22 | $30.29 |
| Average True Range (ATR) | 0.98 | 1.42 |
| MACD | -0.06 | -0.08 |
| Stochastic Oscillator | 66.98 | 34.75 |
Price Performance
Historical ComparisonAbout HASI Hannon Armstrong Sustainable Infrastructure Capital Inc.
HA Sustainable Infrastructure Capital Inc is an investor in sustainable infrastructure assets advancing the energy transition. Its investment is focused on actively partnering with clients to deploy capital in income-generating real assets that are supported by long-term recurring cash flows. This enabled to the generation of attractive risk-adjusted returns and provided stockholders with diversified exposure to the energy transition.
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors.